159 related articles for article (PubMed ID: 30033448)
21. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
22. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.
Tang J; Wang F; Cheng G; Si S; Sun X; Han J; Yu H; Zhang W; Lv Q; Wei JF; Yang H
J Exp Clin Cancer Res; 2018 Feb; 37(1):40. PubMed ID: 29482572
[TBL] [Abstract][Full Text] [Related]
23. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
24. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
He Y; Luo Y; Huang L; Zhang D; Wang X; Ji J; Liang S
Pharmacol Res; 2021 Aug; 170():105732. PubMed ID: 34139345
[TBL] [Abstract][Full Text] [Related]
25. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
28. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Yu S; Dai J; Ma M; Xu T; Kong Y; Cui C; Chi Z; Si L; Tang H; Yang L; Sheng X; Guo J
Cell Death Dis; 2019 Mar; 10(4):254. PubMed ID: 30874541
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
[TBL] [Abstract][Full Text] [Related]
31. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib induces renal cell carcinoma apoptosis
Wang Q; Wu G; Che X; Li Q; Zhang Z; Tang Q
Pharmazie; 2018 Mar; 73(3):156-160. PubMed ID: 29544563
[TBL] [Abstract][Full Text] [Related]
33. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
36. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
Li H; Wang X; Zhang C; Cheng Y; Yu M; Zhao K; Ge W; Cai A; Zhang Y; Han F; Hu Y
Cancer Lett; 2018 Sep; 432():121-131. PubMed ID: 29890207
[TBL] [Abstract][Full Text] [Related]
37. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
Li CY; Yao AM; Chang XN; Guo YH; Xu R
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
[TBL] [Abstract][Full Text] [Related]
38. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
39. Kaempferol Inhibits the Invasion and Migration of Renal Cancer Cells through the Downregulation of AKT and FAK Pathways.
Hung TW; Chen PN; Wu HC; Wu SW; Tsai PY; Hsieh YS; Chang HR
Int J Med Sci; 2017; 14(10):984-993. PubMed ID: 28924370
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
